94 related articles for article (PubMed ID: 8148482)
1. Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin.
van den Besselaar AM; Neuteboom J; Bertina RM
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):895-903. PubMed ID: 8148482
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylethanolamine and phosphatidylserine synergistically promote heparin's anticoagulant effect.
van den Besselaar AM
Blood Coagul Fibrinolysis; 1995 May; 6(3):239-44. PubMed ID: 7654938
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.
Okuda M; Yamamoto Y
Clin Lab Haematol; 2004 Jun; 26(3):215-23. PubMed ID: 15163321
[TBL] [Abstract][Full Text] [Related]
4. Lipid class composition and heparin sensitivity in the activated partial thromboplastin time.
Stevenson KJ; Easton AC; Thomson JM; Poller L
Thromb Haemost; 1983 Aug; 50(2):601-3. PubMed ID: 6636037
[TBL] [Abstract][Full Text] [Related]
5. Standardization of coagulation tests.
Opartkiattikul N
Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
[TBL] [Abstract][Full Text] [Related]
6. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
Francis JL; Howard C
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
[TBL] [Abstract][Full Text] [Related]
7. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
8. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time--the central role of phosphatidyl serine.
Kelsey PR; Stevenson KJ; Poller L
Thromb Haemost; 1984 Oct; 52(2):172-5. PubMed ID: 6441303
[TBL] [Abstract][Full Text] [Related]
9. The effect of membrane composition on the hemostatic balance.
Smirnov MD; Ford DA; Esmon CT; Esmon NL
Biochemistry; 1999 Mar; 38(12):3591-8. PubMed ID: 10090745
[TBL] [Abstract][Full Text] [Related]
10. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
[TBL] [Abstract][Full Text] [Related]
11. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
12. Use of the activated partial thromboplastin time for heparin monitoring.
Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
[TBL] [Abstract][Full Text] [Related]
13. The APTT response of pregnant plasma to unfractionated heparin.
Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
[TBL] [Abstract][Full Text] [Related]
14. Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy.
van den Besselaar AM; Neuteboom J; Meeuwisse-Braun J; Bertina RM
Clin Chem; 1997 Jul; 43(7):1215-22. PubMed ID: 9216459
[TBL] [Abstract][Full Text] [Related]
15. Effect of gentamicin on heparin activity.
Tyler LS; Rehder TL; Davis RB
Am J Hosp Pharm; 1981 Apr; 38(4):537-40. PubMed ID: 7282683
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
Kitchen S; Preston FE
Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
[TBL] [Abstract][Full Text] [Related]
17. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
18. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
Ip BK; Thomson AR; Moriarty HT
Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
[TBL] [Abstract][Full Text] [Related]
20. Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy.
Robinson JL; Tawfik G; Saxinger L; Stang L; Etches W; Lee B
J Antimicrob Chemother; 2005 Nov; 56(5):951-3. PubMed ID: 16155063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
